B. Kilgallen

发表

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

C. Gordon, K. Kalunian, M. Petri, 2013, Annals of the rheumatic diseases.

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

R. Collins, C. Gordon, D. Isenberg, 2016, Arthritis & rheumatology.

Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use

D. Furst, T. Woodworth, V. Sloan, 2019, Drug Safety.

Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study

C. Gordon, K. Kalunian, M. Petri, 2016, Arthritis care & research.

Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals

C. Cooper, D. Gladman, W. Tillett, 2012 .

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus

C. Gordon, K. Kalunian, M. Petri, 2017 .

Efficacy and safety of epratuzumab in patients with moderate / severe active systemic lupus erythematosus : results from EMBLEM , a phase

C. Gordon, K. Kalunian, M. Petri, 2013 .

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

C. Gordon, K. Kalunian, M. Petri, 2013, Rheumatology.

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.

C. Gordon, D. Isenberg, K. Kalunian, 2013, Rheumatology.

Women in a Prenatal Care/Substance Abuse Treatment Program: Links Between Domestic Violence and Mental Health

Jacquelyn C. Campbell, S. Martin, Sandra L Martin, 2004, Maternal and Child Health Journal.

Sexual behaviors and reproductive health outcomes: associations with wife abuse in India.

L. Kupper, K. K. Singh, A. Tsui, 1999, JAMA.

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

D. M. van der Heijde, R. Landewé, A. Deodhar, 2019, Arthritis & rheumatology.

Supplementary Table

C. Gordon, K. Kalunian, M. Petri, 2003 .

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

C. Gordon, K. Kalunian, M. Petri, 2013, Annals of the rheumatic diseases.

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

D. M. van der Heijde, R. Landewé, A. Deodhar, 2019, Arthritis & rheumatology.

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

C. Gordon, K. Kalunian, M. Petri, 2013 .

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

C. Gordon, K. Kalunian, M. Petri, 2013 .

AB0633 Epratuzumab-treated SLE patients report improvements in health-related quality of life: Interim results from a us open-label extension study

V. Strand, K. Hobbs, W. Wegener, 2013 .